Core InitiativesDomain is the inventor and leader of several investment models to translate life sciences innovation into technologies and products that advance health. These include:
Before the advent of institutionalized company creation, Domain started in-house company creation. Companies started through these efforts include Volcano, Glaukos, Orexigen Therapeutics, Zyga Technology and Obalon Therapeutics. Domain’s efforts continue to this day with our involvement with The Foundry, the premier medical device company incubator.
Domain pioneered the model of licensing smaller products from big pharma and growing them into meaningful revenue generators via a specialist-focused sales force. Companies from this model include Dura Pharmaceuticals, Pharmion, SkinMedica and ESP Pharma.
We were early to recognize the potential of in-licensing US rights to Japanese products. Ten companies, including Peninsula Pharmaceuticals, Cerexa, and NovaCardia, have been formed to-date through Japanese in-licensing.
Domain is committed to improving healthcare and proactively identifies areas where we can make a difference. Through our “Disease Day” programs, we bring together experts from industry, academia, medicine, and technology for intensive brainstorming sessions focused on a specific disease area or technology. Within this area, we take an intensive look at healthcare challenges, potential solutions, and investment opportunities. As a result, significant investment initiatives have been made in obesity, Alzheimer’s disease, pain management and molecular diagnostics, to name a few. For a list of our most recent Disease Days, visit our timeline.